Ruria Namba

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA
    Breast Cancer Res 7:R881-9. 2005
  2. ncbi Heterogeneity of mammary lesions represent molecular differences
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California at Davis, Sacramento, CA 95817, USA
    BMC Cancer 6:275. 2006
  3. ncbi Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes
    Jeannie E Maglione
    Department of Medicine, UCSD Cancer Center, School of Medicine, University of California-San Diego, La Jolla, CA, USA
    Mol Cancer Ther 3:941-53. 2004
  4. ncbi Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA
    Clin Cancer Res 12:2613-21. 2006
  5. ncbi Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior
    Alexander D Borowsky
    Department of Medical Pathology and Laboratory Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA
    Clin Exp Metastasis 22:47-59. 2005
  6. ncbi Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California-Davis, Sacramento, California 95817, USA
    Mol Cancer Res 2:453-63. 2004

Detail Information

Publications6

  1. ncbi Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA
    Breast Cancer Res 7:R881-9. 2005
    ..We studied the ovarian-hormone-responsiveness of one of the lines with a particular focus on the effects of two related SERMs, tamoxifen and ospemifene...
  2. ncbi Heterogeneity of mammary lesions represent molecular differences
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California at Davis, Sacramento, CA 95817, USA
    BMC Cancer 6:275. 2006
    ..Each MIN-O line has distinguishable morphologies, metastatic potentials and estrogen dependencies...
  3. ncbi Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes
    Jeannie E Maglione
    Department of Medicine, UCSD Cancer Center, School of Medicine, University of California-San Diego, La Jolla, CA, USA
    Mol Cancer Ther 3:941-53. 2004
    ..These lines provide an opportunity to study the full range of events occurring secondary to PyV-mT expression in the mammary gland...
  4. ncbi Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA
    Clin Cancer Res 12:2613-21. 2006
    ..Although the inhibitory effect of rapamycin was striking, rapamycin treatment did not completely obliterate the lesions...
  5. ncbi Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior
    Alexander D Borowsky
    Department of Medical Pathology and Laboratory Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA
    Clin Exp Metastasis 22:47-59. 2005
    ..Therefore, these two cell lines provide a stable, reproducible resource for the study of metastasis modulators, AKT molecular pathway interactions, and gene target and marker discovery...
  6. ncbi Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California-Davis, Sacramento, California 95817, USA
    Mol Cancer Res 2:453-63. 2004
    ..With consistent tumor latency and molecular profiles, this model provides an experimental platform that can be used to assess functional genomics and molecular pharmacology and to test promising chemoprevention strategies...